Vistagen Therapeutics, Inc. (VTGN) Shareholders’ equity 2016–2026
Vistagen Therapeutics, Inc. (VTGN) shareholders’ equity at each fiscal year-end, per SEC filings.
$35.5MFY2026 · since FY2016: -$3.0M → $35.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $35.5M | -49.5% |
| FY2025 | $70.4M | -38.4% |
| FY2024 | $114.3M | +846.1% |
| FY2023 | $12.1M | -81.3% |
| FY2022 | $64.7M | -29.6% |
| FY2021 | $92.0M | +1705.4% |
| FY2020 | -$5.7M | — |
| FY2018 | $6.9M | +1023.2% |
| FY2017 | $615,800 | +120.7% |
| FY2016 | -$3.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice